Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

• Published in: The New England journal of medicine Vol. 391; no. 10; pp. 885 - 898
• Main Authors: Hochhaus, Andreas, Wang, Jianxiang, Kim, Dong-Wook, Kim, Dennis Dong Hwan, Mayer, Jiri, Goh, Yeow-Tee, le Coutre, Philipp, Takahashi, Naoto, Kim, Inho, Etienne, Gabriel, Andorsky, David, Issa, Ghayas C., Larson, Richard A., Bombaci, Felice, Kapoor, Shruti, McCulloch, Tracey, Malek, Kamel, Yau, Lillian, Ifrah, Sophie, Hoch, Matthias, Cortes, Jorge E., Hughes, Timothy P.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 12.09.2024
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; BCR-ABL protein; Chi-square test; Chronic myeloid leukemia; Confidence intervals; Disease control; Female; Fusion Proteins, bcr-abl - antagonists & inhibitors; Fusion Proteins, bcr-abl - genetics; Hematology; Humans; Hypotheses; Imatinib; Imatinib Mesylate - adverse effects; Imatinib Mesylate - therapeutic use; Inhibitor drugs; Kaplan-Meier Estimate; Kinases; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Lymphoma; Male; Middle Aged; Myeloid leukemia; Niacinamide - administration & dosage; Niacinamide - adverse effects; Niacinamide - analogs & derivatives; Oncology; Patients; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Quality of life; Statistical analysis; Targeted cancer therapy; Treatment Outcome; Treatments in Oncology; Tyrosine kinase inhibitors; Tyrosine Kinase Inhibitors - administration & dosage; Tyrosine Kinase Inhibitors - adverse effects; Young Adult
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2400858

Asciminib, an agent that targets the myristoyl pocket of BCR::ABL, was compared with imatinib and with imatinib plus second-generation tyrosine kinase inhibitors. Outcomes were better with asciminib in both comparisons.